AstraZeneca heart disease trial failure raises efficacy concerns for silencer drug class

AstraZeneca has disclosed the failure of a late-stage clinical trial for a heart disease drug, prompting industry-wide scrutiny of the 'silencer' drug mechanism. The unexpected results create uncertainty regarding the viability of similar therapeutic pipelines in a multi-billion dollar market.